pdf   xlsx method abbreviations

breast cancer - HER2-positive, tucatinib plus trastuzumab plus capecitabine , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.66 [0.50, 0.88]< 10%1 study (1/-)99.8 %NAnot evaluable crucial-
progression or deaths (PFS) 0.54 [0.42, 0.70]< 10%1 study (1/-)100.0 %NAnot evaluable important-

safety endpoints 00

AE leading to treatment discontinuation (any grade) 1.92 [0.77, 4.80]< 10%1 study (1/-)8.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.